ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 May 2019
Last Updated on 01 Sep 2020
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Ursodeoxycholic acid 250 mg capsule, 500 mg tablet and 50 mg/ml suspension for treating primary biliary cirrhosis in patients without decompensated hepatic cirrhosis.

Subsidy status
Ursodeoxycholic acid 250 mg capsule, 500 mg tablet and 50 mg/ml suspension are recommended for inclusion on the MOH Standard Drug List (SDL).

Ursodeoxycholic acid 50 mg/ml suspension does not have regulatory approval with the Health Sciences Authority (HSA). The responsibility of prescribing an unregistered product to patients lies with the treating clinician. Before treatment is started, it is important to consider the availability of other suitable registered alternatives and inform the patient or their carer that the product is unregistered.

Ursodeoxycholic acid for treating primary biliary cirrhosis (updated 1 Sept 2020) Ursodeoxycholic acid for treating primary biliary cirrhosis PES (updated 1 Sept 2020)